Your body's ability to absorb iron from food is not just about what you eat — it is tightly controlled by a hormonal gatekeeper called hepcidin¹¹ hepcidin
A 25-amino-acid peptide hormone produced by the liver that acts as the master regulator of systemic iron homeostasis. Hepcidin blocks ferroportin²² ferroportin
The only known mammalian cellular iron exporter, present on the surface of enterocytes (gut lining cells) and macrophages, the only iron export channel on gut cells, effectively slamming the door on iron absorption when levels are sufficient. The TMPRSS6 gene encodes matriptase-2³³ matriptase-2
A type II transmembrane serine protease expressed primarily in the liver, a liver enzyme whose job is to keep hepcidin in check by cleaving hemojuvelin⁴⁴ hemojuvelin
A membrane-bound co-receptor that activates the BMP/SMAD signaling pathway, which drives hepcidin transcription on the cell surface. When matriptase-2 works well, hepcidin stays low and iron flows freely from the gut into the bloodstream. When it does not, hepcidin rises and iron absorption drops.

The Ala736Val variant (rs855791) sits in the catalytic domain of matriptase-2 — the business end of the enzyme. The A allele (Val736) reduces the enzyme's ability to suppress hepcidin, resulting in higher hepcidin levels and lower iron absorption. This is not a rare mutation causing disease. It is a common polymorphism carried by roughly half of Europeans and over half of East Asians, making it the single strongest common genetic determinant of iron status identified by genome-wide association studies.

The Mechanism

Matriptase-2 normally cleaves hemojuvelin from the liver cell surface, disabling the BMP/SMAD signaling pathway⁵⁵ BMP/SMAD signaling pathway
Bone morphogenetic protein / son of mothers against decapentaplegic — a signaling cascade that drives hepcidin gene transcription in hepatocytes that drives hepcidin production. The Val736 form of matriptase-2 is less efficient at this cleavage. In vitro experiments⁶⁶ In vitro experiments
Nai A et al. TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood, 2011 demonstrated that cells expressing the Ala736 form suppress hepcidin transcription more effectively than those expressing Val736. In living people, this translates to measurable differences: Ala736 homozygotes have lower serum hepcidin, higher transferrin saturation, and higher serum iron compared to Val736 homozygotes.

The downstream consequence is straightforward. Higher hepcidin means more ferroportin gets internalized and degraded on gut enterocytes. Less ferroportin means less iron crosses from the gut lining into the bloodstream. The effect is dose-dependent — each copy of the A allele (Val736) incrementally raises hepcidin and lowers iron absorption.

The Evidence

Two landmark genome-wide association studies published simultaneously in 2009 identified rs855791 as the top hit for iron-related traits. Benyamin et al.⁷⁷ Benyamin et al.
Benyamin B et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet, 2009 found associations with serum iron (P = 1.5 x 10^-20), transferrin saturation (P = 2.2 x 10^-23), and mean corpuscular volume (P = 1.1 x 10^-10). Each copy of the risk allele decreased serum iron and transferrin saturation by 0.18 and 0.20 standard deviations respectively, explaining about 2% of population variance in these traits. Chambers et al.⁸⁸ Chambers et al.
Chambers JC et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet, 2009 reported that each A allele copy lowered hemoglobin by 0.13 g/dL, with AA homozygotes averaging 0.2 g/dL lower hemoglobin than GG homozygotes.

A stable iron isotope study⁹⁹ stable iron isotope study
Buerkli S et al. The TMPRSS6 variant (SNP rs855791) affects iron metabolism and oral iron absorption — a stable iron isotope study in Taiwanese women. Haematologica, 2021 directly measured iron absorption using labeled iron meals. At equivalent low iron stores (ferritin 15 ug/L), women with the CC genotype (Ala/Ala on the coding strand, GG on 23andMe) absorbed 26.6% of the iron dose, while TT women (Val/Val, AA on 23andMe) absorbed only 18.5% — a roughly 30% reduction in iron absorption capacity.

A systematic review¹⁰¹⁰ systematic review
Gichohi-Wainaina WN et al. Inter-ethnic differences in genetic variants within the transmembrane protease, serine 6 (TMPRSS6) gene associated with iron status indicators. Genes Nutr, 2015 confirmed that the A allele is consistently associated with approximately 0.11 g/dL lower hemoglobin across populations.

Practical Implications

For people with the AA genotype who already have adequate iron stores, this variant is clinically silent. The effect matters most when iron demand is high or dietary intake is marginal — during menstruation, pregnancy, rapid growth, vegetarian or vegan diets, or endurance athletics. In these contexts, a 30% reduction in absorption efficiency can tip the balance toward deficiency.

Iron absorption can be optimized by pairing iron-rich foods with vitamin C, choosing heme iron sources¹¹¹¹ heme iron sources
Heme iron from meat, poultry, and fish is absorbed 2-3 times more efficiently than non-heme iron from plants, and its absorption is less affected by hepcidin when possible, and avoiding calcium, tea, and coffee at iron-containing meals. For those who need supplements, iron bisglycinate¹²¹² iron bisglycinate
A chelated form of iron that is absorbed via a different pathway (peptide transporters) and is less affected by hepcidin-mediated ferroportin degradation may be preferable to ferrous sulfate because it is partially absorbed through peptide transporters rather than ferroportin alone.

Monitoring is simple: a serum ferritin test (ideally with transferrin saturation) tells you whether your iron stores are adequate. A ferritin below 30 ug/L suggests depleted stores even if hemoglobin is still normal.

Interactions

TMPRSS6 rs855791 interacts with rs4820268, another TMPRSS6 variant in linkage disequilibrium that independently affects iron parameters. More importantly, it interacts with HFE variants¹³¹³ HFE variants
HFE encodes a protein that also regulates hepcidin. The C282Y (rs1800562) and H63D (rs1799945) variants in HFE cause hereditary hemochromatosis by reducing hepcidin, leading to iron overload. In hereditary hemochromatosis (HFE C282Y homozygotes), the Val736 allele of TMPRSS6 acts as a protective modifier — its hepcidin-raising effect partially counteracts the hepcidin-lowering effect of HFE mutations, and Val736 carriers show reduced risk of cirrhosis¹⁴¹⁴ Val736 carriers show reduced risk of cirrhosis
Valenti L et al. Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis. J Hepatol, 2012 and hepatocellular carcinoma compared to Ala736 homozygotes.

Conversely, carrying both the AA genotype at rs855791 and being a menstruating woman, a vegetarian, or an endurance athlete compounds iron loss risk — these are the individuals most likely to benefit from proactive monitoring and dietary optimization.

Interleukin-13¹¹ Interleukin-13
IL-13 is a Th2 cytokine secreted by mast cells, basophils, ILC2 innate lymphoid cells, and activated CD4+ T cells; it drives IgE class switching, mucus hypersecretion, skin barrier remodeling, and airway smooth-muscle hyperresponsiveness is one of the most potent mediators of allergic inflammation in humans. While the better-known rs20541 variant changes the amino acid sequence of the IL-13 protein (p.Arg130Gln), rs1295685 sits 481 base pairs downstream at position chr5:132660753 in the 3' untranslated region (UTR) of the IL13 gene. It does not alter the protein — instead, it lies in a region of the mRNA that controls how long the transcript persists in cells and how efficiently it is translated. These 3'-UTR regulatory variants can influence gene expression as powerfully as coding changes, particularly for cytokines like IL-13 whose secretion is tightly gated by post-transcriptional regulation.

The Mechanism

The 3'-UTR of mRNA contains binding sites for microRNAs and RNA-binding proteins that collectively determine transcript stability and translation rate. A single-nucleotide variant in this region can disrupt or create a microRNA binding site, shifting the equilibrium of IL-13 production upward or downward across immune cells. rs1295685 lies within the IL13 3'-UTR on the plus strand (GRCh38 chr5:132660753), where the minor A allele is the GRCh38 reference but the population-major G allele (~80% globally) represents the baseline regulatory configuration. The A allele — present in approximately 20% of European chromosomes — is found almost exclusively on the same haplotype as the rs20541 Q130 risk allele, confirmed by haplotype analysis in Japanese cohorts²² haplotype analysis in Japanese cohorts
Lee et al. Ann Allergy Asthma Immunol 2020; fine-mapping of IL13 in 495 cases and 444 controls with independent replication in 757 cases and 1,620 controls; rs1295685 showed P=0.01 for AD association in the pilot study. This strong linkage disequilibrium means the two variants tag the same risk haplotype block rather than independently affecting IL-13 biology. The clinical consequence of carrying the A allele is the same as for rs20541-A: higher constitutive IL-13 pathway activity, measurably elevated serum IgE, and greater lifetime risk for atopic disease.

The Evidence

The IL13 5q31 locus is one of the most consistently replicated genomic regions in allergy genetics. A 2023 European and multi-ancestry GWAS meta-analysis³³ 2023 European and multi-ancestry GWAS meta-analysis
Budu-Aggrey et al., Nature Communications; European discovery: ~21,000 AD cases and ~95,000 controls; 23andMe replication: 2.9 million individuals placed the 5q31 IL13 locus at P<10⁻³⁶ for atopic dermatitis, one of the strongest genetic signals in all of human atopy genetics. rs1295685 sits within this implicated haplotype block. Fine-mapping work in [Japanese AD cohorts (495 cases, 444 controls pilot; 757 cases, 1,620 controls replication) | Lee et al. 2020](https://pubmed.ncbi.nlm.nih.gov/32371243/) established that both rs20541 and rs1295685 are significantly associated with atopic dermatitis, and that haplotypes containing both variants confer disease risk (minimum P=0.006). The same study confirmed strong LD between these two IL13 variants, locating the primary functional driver within the rs20541 coding change while acknowledging that rs1295685 marks the same risk haplotype. Fine-mapping of serum IgE loci in [>1,300 German children | Sharma et al. Allergy 2014](https://pubmed.ncbi.nlm.nih.gov/24930997/⁴⁴ https://pubmed.ncbi.nlm.nih.gov/24930997/) confirmed the 5q31 region — containing both IL13 variants — as a major susceptibility locus for elevated total serum IgE, the primary biological readout of sustained IL-13-driven B-cell class-switching.

Because rs1295685 is a 3'-UTR variant, it may also have a regulatory contribution that is independent of rs20541 at the mRNA level — 3'-UTR polymorphisms in cytokine genes frequently modulate transcript stability and production kinetics in ways that complement coding changes. However, the current evidence does not permit separating a 3'-UTR-specific regulatory effect from haplotype tagging; both mechanisms may contribute.

Practical Implications

The clinical implications of carrying the rs1295685 A allele are directly parallel to those of rs20541-A, because the variants co-segregate on the same haplotype in nearly all carriers. Elevated serum IgE, heightened susceptibility to atopic dermatitis, allergic rhinitis, and eczema, and a greater tendency to mount Th2 responses to environmental allergens are the principal consequences. For carriers with active atopic disease inadequately controlled by topical therapies, IL-13-pathway biologics (tralokinumab, dupilumab) represent a genetically rationale treatment pathway. Measuring serum total IgE and periostin provides a quantitative readout of how biologically active the IL-13 pathway is in the individual carrier, and documents eligibility for biologic therapy.

Interactions

rs1295685 lies in strong LD with rs20541 (IL13 R130Q) — these two variants tag the same risk haplotype. Carriers of the A allele at rs1295685 almost invariably also carry the A allele at rs20541, so the combined functional consequence represents compound within-gene effects on IL-13: one variant alters the protein surface charge (rs20541), the other potentially alters mRNA stability and translation rate (rs1295685).

The rs1801275 variant (IL-4Rα R576Q) alters the shared IL-4Rα signal transduction subunit used by both IL-4 and IL-13 receptors. Individuals carrying both rs1295685-A (IL13 UTR risk haplotype) and rs1801275 risk allele may face additive Th2 dysregulation — enhanced IL-13 production meeting altered receptor signal transduction — a mechanistic interaction relevant to dupilumab pharmacogenomics, since dupilumab targets IL-4Rα directly.

The rs2040704 variant in RAD50/TH2LCRR upstream of IL13 tags an enhancer hub that coordinates IL-4, IL-5, and IL-13 expression. Carriers of rs1295685-A alongside the rs2040704 risk haplotype may face compounding Th2 amplification via both cisregulatory (enhancer-level) and UTR-level effects on IL-13 expression.

The TMPRSS3 gene encodes a type II transmembrane serine protease¹¹ type II transmembrane serine protease
Anchored to the cell membrane with its catalytic domain facing the extracellular space; expressed in cochlear inner hair cells, outer hair cells, spiral ganglion neurons, and the stria vascularis essential for the survival and maturation of cochlear hair cells. TMPRSS3 is unusual among serine proteases in that it undergoes autocatalytic activation — the full-length single-chain zymogen must cleave itself at a specific arginine residue to release the active catalytic domain. The p.Arg216Leu substitution strikes this cleavage site directly, converting the critical arginine to leucine and locking the protein permanently in its inactive zymogen form.

This variant was identified in two Turkish brothers with non-syndromic deafness born to consanguineous parents²² identified in two Turkish brothers with non-syndromic deafness born to consanguineous parents
Wattenhofer M et al., Human Genetics 2005, screening 25 Turkish families; R216L found homozygous in the affected siblings; the mutation was the highest-scoring TMPRSS3 mutation for LOD score linkage to chr21q22.3 in that cohort. It is catalogued in ClinVar (variation 4946) as pathogenic for autosomal recessive nonsyndromic hearing loss 8 (DFNB8), with OMIM allelic entry 605511.0005.

The Mechanism

TMPRSS3 is synthesized as an inactive single-chain precursor (zymogen). Activation requires autocatalytic cleavage at arginine 216³³ arginine 216
The canonical serine protease activation motif contains a conserved arginine or lysine immediately preceding the catalytic domain; cleavage here releases the prodomain and exposes the active-site triad, which generates the active two-chain form held together by a disulfide bond. This processing step is obligatory for all downstream activity.

The p.Arg216Leu substitution replaces the cleavage-site arginine with leucine — an amino acid that the protease cannot recognize as a cleavage substrate. Functional characterization in Xenopus oocytes⁴⁴ Functional characterization in Xenopus oocytes
Wattenhofer 2005 used the well-validated oocyte expression system to measure both autocatalytic processing and ENaC activation; neither occurred with R216L TMPRSS3 confirmed that the R216L mutant protein: (1) fails to undergo proteolytic self-cleavage, and (2) is completely unable to activate the epithelial sodium channel (ENaC). This distinguishes R216L from hypomorphic missense variants (such as p.Ala306Thr, which retains partial activity) — R216L produces a functional null.

The downstream cochlear consequence is hair cell degeneration. In mouse models, Tmprss3-deficient cochleae show normal morphology at birth but undergo rapid progressive hair cell loss beginning at postnatal day 12⁵⁵ Tmprss3-deficient cochleae show normal morphology at birth but undergo rapid progressive hair cell loss beginning at postnatal day 12
The onset coincides exactly with the moment hearing activates in mice; loss begins in the high-frequency basal cochlear turn and sweeps toward the apex, consistent with the down-sloping audiogram seen in human DFNB8 — the same postnatal timing when the organ of Corti first becomes mechanically and electrically active.

The Evidence

Functional evidence is conclusive. The 2005 Wattenhofer study provided direct biochemical proof that R216L abolishes TMPRSS3 activity through loss of autocatalytic processing. This is one of only a handful of TMPRSS3 variants with complete functional nullification confirmed in a heterologous expression system⁶⁶ This is one of only a handful of TMPRSS3 variants with complete functional nullification confirmed in a heterologous expression system
Most TMPRSS3 missense variants have not been functionally characterized; R216L and p.Ala306Thr are the best-characterized variants in the literature.

Population context. TMPRSS3 accounts for approximately 11% of autosomal recessive nonsyndromic hearing loss in Turkish populations⁷⁷ TMPRSS3 accounts for approximately 11% of autosomal recessive nonsyndromic hearing loss in Turkish populations
Compared to <1% in Caucasians, 0.7% in Japanese, 3% in Pakistani, 4.6% in Chinese, 5–6% in Tunisian, and 5.9% in Korean populations — Turkish prevalence is the highest documented, making it the highest-prevalence population for this gene. The R216L allele was specifically characterized in a Turkish family, and given the high TMPRSS3 burden in Turkish populations, this allele likely contributes to a meaningful fraction of Turkish ARNSHL cases. In gnomAD, the A allele at chr21:42383168 (the R216L plus-strand allele) appears at a global frequency of approximately 0.003% — consistent with a rare recessive pathogenic allele maintained at low frequency by heterozygous carrier state.

Genotype-phenotype correlation. A comprehensive genotype-phenotype analysis⁸⁸ comprehensive genotype-phenotype analysis
Nisenbaum et al. Audiology & Neurotology 2023, reviewing all published TMPRSS3 cases with natural history data established that biallelic severe/null TMPRSS3 alleles produce prelingual profound deafness (DFNB10), while combinations of one null allele with one missense allele typically produce postlingual progressive hearing loss (DFNB8) with a characteristic down-sloping audiogram progressing at approximately 0.3 dB per year⁹⁹ 0.3 dB per year
This rate applies to DFNB8 phenotype; DFNB10 patients present with congenital profound deafness and show essentially no residual cochlear function by audiometric testing. Because R216L is a functional null, homozygous R216L individuals would be expected to manifest DFNB10 (congenital profound deafness), while compound heterozygotes carrying R216L on one allele and a milder missense variant on the other might present with DFNB8 progressive loss.

Cochlear implantation outcomes in TMPRSS3-related hearing loss are excellent and consistent across populations¹⁰¹⁰ excellent and consistent across populations
International cohort of 127 patients, 16 centers, 6 countries; mean word recognition score 76% at follow-up. Age at implantation — not genotype — is the principal predictor of speech recognition outcome, with each year of delay associated with a measurable decrement in outcome. This makes early diagnosis and timely implantation the most critical clinical interventions.

Practical Implications

For confirmed homozygous (AA) individuals, this information directly supports early hearing intervention. For heterozygous (AC) carriers, hearing is expected to be normal but carrier status is clinically important for reproductive planning, particularly given the elevated TMPRSS3 carrier frequency in Turkish and other Middle Eastern populations.

For any individual with this variant, standard hearing health practices do not require modification — TMPRSS3-related hearing loss does not respond to dietary, supplement, or pharmacological interventions. The clinical value is entirely in diagnosis (confirming the cause of hearing loss in affected individuals), prognosis (predicting progression), and reproductive counseling (assessing offspring risk in carrier couples).

Interactions

The primary interaction is with other TMPRSS3 pathogenic alleles. Biallelic TMPRSS3 mutations can arise from homozygosity (two copies of the same allele, as in the original Turkish family carrying two R216L copies) or compound heterozygosity (one copy of R216L on one chromosome and a different pathogenic allele on the other). Given the diversity of TMPRSS3 pathogenic alleles documented across populations — including rs727503493 (c.208delC frameshift) and rs45598239 locus variants — comprehensive TMPRSS3 panel sequencing is required to identify compound heterozygotes, who will have two different pathogenic alleles.

A possible digenic interaction with GJB2¹¹¹¹ A possible digenic interaction with GJB2
GJB2 encodes connexin 26, the most common cause of ARNSHL in Caucasians (c.35delG allele, rs80338939); initial case reports suggested TMPRSS3/GJB2 digenic inheritance, later disputed by larger series has been proposed but is not confirmed. In clinical practice, when a single TMPRSS3 pathogenic allele is found in an individual with hearing loss, comprehensive deafness gene panel testing — including GJB2 — is warranted.

HNF4A (Hepatocyte Nuclear Factor 4 Alpha) is a master transcription factor that controls hundreds of genes in pancreatic beta cells and the liver. Unlike the common polygenic variants that nudge diabetes risk by a few percent, a pathogenic variant in HNF4A rewrites your entire metabolic trajectory¹¹ rewrites your entire metabolic trajectory
HNF4A sits at the top of a transcription factor cascade: it regulates HNF1A, which regulates genes needed for glucose-stimulated insulin secretion. This is MODY1 — Maturity-Onset Diabetes of the Young, type 1 — and it follows a trajectory unlike any common form of diabetes: paradoxical hyperinsulinism at birth, followed by progressive insulinopenia in adulthood.

The Mechanism

The c.763C>T variant introduces a premature stop codon at position 277 (p.Gln277Ter), truncating the protein and deleting the C-terminal 187 amino acids. The truncated protein loses its transcriptional transactivation activity — it cannot dimerize, cannot bind DNA, and cannot activate target genes²² cannot dimerize, cannot bind DNA, and cannot activate target genes
Stoffel & Duncan 1997 showed the Q268X truncated protein had no DNA-binding activity in reporter assays and failed to transactivate HNF4A target genes. Because HNF4A is required for normal transcription of genes driving glucose-stimulated insulin secretion in pancreatic beta cells, haploinsufficiency — one functional copy instead of two — causes progressive loss of beta-cell response to glucose.

The temporal paradox is striking: in the fetal and neonatal period, the same mutation causes excessive insulin secretion³³ same mutation causes excessive insulin secretion
Mice with beta-cell deletion of Hnf4a show hyperinsulinism in utero and hyperinsulinemic hypoglycemia at birth, confirming the mechanism, producing macrosomia and neonatal hypoglycemia. Over years, beta-cell capacity declines progressively, and insulinopenic diabetes emerges — usually in the second or third decade of life.

The Evidence

The landmark 1996 study by Yamagata et al.⁴⁴ landmark 1996 study by Yamagata et al.
Yamagata K et al. Mutations in the hepatocyte nuclear factor-4alpha gene in maturity-onset diabetes of the young (MODY1). Nature, 1996 identified HNF4A as the gene responsible for MODY1 in the historic RW pedigree — a six-generation Michigan family with 74 affected members studied prospectively since 1958. The Q268X mutation (equivalent to Q277X on current reference transcripts) was the founding pathogenic variant in this family.

The neonatal phenotype was quantified by Pearson et al. in 107 HNF4A mutation carriers⁵⁵ Pearson et al. in 107 HNF4A mutation carriers
Pearson ER et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLOS Medicine, 2007: 56% of carriers were macrosomic (mean birth weight 4,450 g), a median 790 g heavier than unaffected siblings (p<0.001). Transient neonatal hypoglycemia occurred in 15% of carriers — versus none of the unaffected family members.

For treatment, Crowley et al. 2025⁶⁶ Crowley et al. 2025
Crowley MT et al. Sulphonylurea efficacy and end-organ outcomes in the management of HNF4A-MODY. Diabetic Medicine, 2025 followed HNF4A-MODY patients on sulfonylurea monotherapy for six years: 51.6% achieved significant HbA1c reduction (p=0.045), with responders maintaining HbA1c at 45 mmol/mol (6.3%) compared to 58 mmol/mol (7.5%) before treatment. Responders tended to be younger with shorter disease duration — arguing for early diagnosis and early initiation.

Mirshahi et al. 2022⁷⁷ Mirshahi et al. 2022
Mirshahi UL et al. Reduced penetrance of MODY-associated HNF1A/HNF4A variants but not GCK variants in clinically unselected cohorts. Am J Hum Genet, 2022 found that penetrance varies dramatically by discovery context: 98% in clinical referral cohorts by age 40, but only 5–17% in population health system cohorts. This means that an HNF4A pathogenic variant found incidentally in a healthy adult carries lower disease probability than the same variant found in a referred diabetic patient — context matters for counseling.

Practical Actions

The most important single thing a carrier can do: obtain a definitive genetic diagnosis and discuss transition to sulfonylurea therapy with a specialist in monogenic diabetes. Sulfonylureas bypass the impaired glucose-stimulated insulin secretion by directly stimulating the KATP channel in beta cells — they work where the genetic defect cannot. HNF4A-MODY patients often respond dramatically better to low-dose sulfonylurea than to insulin.

Pregnancy requires special management: glibenclamide crosses the placenta at ~70% of maternal levels, amplifying the genetic tendency toward macrosomia and neonatal hypoglycemia. Women on sulfonylurea should transition to insulin before conception or by the second trimester. Neonatal glucose monitoring is mandatory for all newborns of HNF4A carriers, regardless of the father's or mother's glycemic control.

Family screening is strongly indicated: with 50% inheritance probability and high penetrance in the clinical setting, first-degree relatives of a confirmed MODY1 carrier should all have genetic testing offered.

Interactions

HNF4A sits directly upstream of HNF1A (MODY3) in the transcription factor hierarchy — HNF4A activates HNF1A transcription, and HNF1A in turn regulates many of the same beta-cell function genes. Rare patients carry pathogenic variants in both HNF4A and HNF1A (digenic MODY), presenting with earlier onset and more severe disease than either mutation alone. If a first-degree relative has a known HNF1A pathogenic variant, combined panel testing covering HNF4A, HNF1A, GCK, HNF1B, and other MODY genes is preferred over single-gene testing.

The MTRR gene (methionine synthase reductase) runs a critical maintenance reaction in the methylation cycle. Methionine synthase (MTR) converts homocysteine back to methionine using vitamin B12 as a cofactor, but in doing so it oxidizes its own cobalamin ¹¹ Cobalamin: the cobalt-containing form of vitamin B12 that acts as the cofactor for MTR cofactor to an inactive form. MTRR's sole job is to reactivate this oxidized B12, keeping MTR running. If MTRR works less efficiently, MTR stalls and homocysteine accumulates — but only when B12 supply is tight.

The Mechanism

The S175L missense variant (c.524C>T) substitutes a serine for leucine at position 175 of the MTRR protein. Serine and leucine differ significantly in polarity: serine is hydrophilic, leucine is hydrophobic. Position 175 lies in a functional domain of MTRR, and the amino acid swap is thought to reduce the enzyme's efficiency at reactivating the cobalamin cofactor. Critically, this effect is only unmasked when intracellular B12 is in short supply — when B12 is adequate, the pathway appears to compensate. Riboflavin (vitamin B2) is also a cofactor for MTRR via its FMN ²² Flavin mononucleotide — the active form of riboflavin used as an electron carrier in MTRR domain, so riboflavin status modulates the variant's downstream impact.

The Evidence

The clearest data on rs1532268 comes from a Spanish population study of 771 adults³³ Spanish population study of 771 adults
García-Minguillán CJ et al. Riboflavin status modifies the effects of MTHFR and MTRR polymorphisms on homocysteine. Genes Nutr, 2014. T-allele carriers had 13.7% higher plasma homocysteine when cobalamin was low (≤273 pmol/L, lowest quartile) compared to CC individuals (p < 0.01). When cobalamin was in the upper quartiles, no difference was observed. This gene–environment interaction identifies the key lever: B12 status.

For cancer risk, a meta-analysis of five studies pooling 2800 gastric cancer cases and 2679 controls⁴⁴ meta-analysis of five studies pooling 2800 gastric cancer cases and 2679 controls
Zhong G et al. MTRR rs1532268 polymorphism and gastric cancer risk. J Int Med Res, 2022 found the T allele increases gastric cancer risk by approximately 14% (OR 1.14, 95% CI 1.01–1.29). A separate Korean case-control study⁵⁵ Korean case-control study
Lu YT et al. Riboflavin intake, MTRR genetic polymorphism rs1532268 and gastric cancer risk. Br J Nutr, 2022 (377 cases, 756 controls) showed that T-allele carriers with low riboflavin intake had 93% higher gastric cancer risk (OR 1.93, 95% CI 1.09–3.42), while adequate riboflavin appeared protective.

For drug interactions, pediatric ALL patients with the CT or TT genotype showed significantly higher methotrexate serum concentrations⁶⁶ significantly higher methotrexate serum concentrations
PMID 35434830 at 24 hours than CC patients (p = 0.04), suggesting altered folate pathway pharmacokinetics that may affect toxicity monitoring.

Practical Actions

The actionable insight from this variant is B12-centric: maintaining adequate cobalamin removes the functional penalty of the T allele. Methylcobalamin — the active form that directly participates in the MTR-MTRR cycle — is the preferred supplemental form. Riboflavin status also matters; T-allele carriers on low riboflavin diets face compounded gastric cancer risk, and riboflavin is a cheap, safe supplement. Periodic monitoring of plasma homocysteine provides a functional readout of whether the methylation cycle is running smoothly.

Interactions

MTRR S175L sits directly upstream of MTR (rs1805087, A2756G), which it reactivates. If both MTR and MTRR are running suboptimally, the homocysteine-to-methionine conversion is compromised from two directions simultaneously. MTHFR (rs1801133, C677T) is an upstream pathway partner supplying the methyl-THF substrate for MTR; compound impairment across MTHFR + MTRR + MTR (the "methylation triple") represents the strongest case for targeted B-vitamin supplementation in this pathway. MTRR A66G (rs1801394) is the most studied MTRR variant and is well-established as a functional variant; rs1532268 likely acts independently given its location in a different exon.

The PPARG gene encodes Peroxisome Proliferator-Activated Receptor Gamma¹¹ Peroxisome Proliferator-Activated Receptor Gamma
PPARγ is a nuclear transcription factor that acts as the master regulator of fat cell formation and insulin sensitization, the protein that coordinates adipocyte differentiation and insulin sensitization. It is also the molecular target of thiazolidinedione²² Thiazolidinediones (e.g., pioglitazone, rosiglitazone) are diabetes drugs that bind and activate PPARγ, improving insulin sensitivity drugs used in treating type 2 diabetes. rs17036314 is an intronic variant in PPARG — it does not change the protein sequence itself but sits within a regulatory region of the gene that influences transcriptional output in metabolically active tissues.

The Mechanism

As an intronic variant, rs17036314 likely affects how efficiently or in what pattern PPARG is expressed in insulin-responsive tissues such as skeletal muscle and adipose tissue. The C allele tags a haplotype block in PPARG intron 2 that is associated with higher fasting plasma glucose at baseline and greater risk of progressing from impaired glucose tolerance³³ impaired glucose tolerance
A pre-diabetic state: fasting glucose 100-125 mg/dL or 2-hour post-load glucose 140-199 mg/dL to frank type 2 diabetes. Critically, the risk effect is not fixed: increased aerobic physical activity appears to override the genetic predisposition, restoring normal glucose regulation trajectories in C carriers who become more active.

The Evidence

The primary study is the Finnish Diabetes Prevention Study (DPS), a multi-center randomized trial in which 479 overweight individuals with impaired glucose tolerance were followed for an average of 4.2 years with annual physical activity assessment. Lindi et al. 2007⁴⁴ Lindi et al. 2007
Lindi et al. SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Med Sci Sports Exerc 2008;40(1):25-33 found that C allele carriers had significantly higher fasting glucose at baseline and that the rare C allele predicted conversion to T2D (P = 0.038); uniquely among the seven PPARG SNPs studied, this association remained after adjustment for baseline fasting glucose (P = 0.030). Most importantly, the interaction test between change in physical activity and rs17036314 was highly significant (P = 0.002): participants who substantially increased their activity level showed no excess T2D risk from the C allele, while those who remained sedentary retained the elevated risk.

Although the effect estimate for this intronic variant is modest in cross-sectional GWAS settings, the gene-environment interaction is one of the strongest replicated exercise-by-genotype interactions in the T2D prevention literature. The variant has also been genotyped in a Sudanese candidate-gene study of T2D loci (Mtiraoui et al. 2016⁵⁵ Mtiraoui et al. 2016
Mtiraoui et al. Candidate gene analysis supports a role for polymorphisms at TCF7L2 as risk factors for type 2 diabetes in Sudan. J Diabetes Res 2016), supporting relevance across diverse populations.

Practical Actions

For C allele carriers, the evidence strongly supports aerobic exercise as a primary metabolic intervention — not just for general fitness, but specifically to override the genetic risk this variant confers. The DPS data indicate that increasing total weekly physical activity volume is the lever: participants who moved from low activity to above-median activity abolished the C-allele risk. Monitoring fasting glucose and HbA1c provides objective feedback on whether the intervention is working.

Interactions

rs17036314 shares a gene with rs1801282 (PPARG Pro12Ala), the most studied PPARG variant. In the Finnish DPS, both variants predicted T2D conversion, and both interacted with physical activity. They likely tag different functional haplotypes within PPARG and can compound. The PPARD variant rs2016520 and PPARGC1A rs8192678 (Gly482Ser) operate in the same transcriptional pathway; one study found that combinations of these PPAR-family variants predicted IGT-to-T2D conversion better than any single variant alone.

Your body cannot make DHA from scratch. It relies on a metabolic relay: dietary alpha-linolenic acid (ALA) from plants is converted step by step — first to EPA, then elongated to DPA, and finally to DHA. The last two elongation steps in this relay are performed by ELOVL2, elongation of very long chain fatty acids protein 2¹¹ elongation of very long chain fatty acids protein 2
An endoplasmic reticulum enzyme that catalyses the rate-limiting elongation of EPA (20:5n-3) to DPA (22:5n-3) and then DPA to DHA (22:6n-3). DHA is the dominant structural fatty acid in the brain's grey matter and in photoreceptor cell membranes of the retina. The rs17606561 variant sits in the 3' untranslated region (3'UTR)²² 3' untranslated region (3'UTR)
The non-coding sequence at the end of an mRNA that controls message stability, translation efficiency, and miRNA binding — variants here can alter how much protein a gene produces without changing the protein's sequence of ELOVL2, where it may influence how efficiently the gene is expressed.

The Mechanism

Unlike missense variants that change ELOVL2's protein structure, this 3'UTR variant likely affects gene regulation — potentially altering ELOVL2 mRNA stability or its binding to microRNAs³³ microRNAs
Small non-coding RNA molecules that bind to mRNA 3'UTR sequences and suppress translation or promote degradation, fine-tuning protein output. The net effect is a shift in the EPA→DPA→DHA conversion step. Carriers of the A allele show a pattern consistent with partial ELOVL2 insufficiency⁴⁴ partial ELOVL2 insufficiency
Lower endogenous DHA synthesis capacity, reflected in reduced baseline DHA proportions in plasma phospholipids, with upstream EPA and DPA accumulating or being redirected: lower baseline circulating DHA despite normal EPA intake, with a compensatory up-regulation of the pathway in response to exogenous EPA/DHA — which is why minor allele carriers show a larger DHA response to fish oil supplementation.

The Evidence

The clearest evidence for ELOVL2 variants affecting omega-3 metabolism comes from the CHARGE Consortium meta-analysis⁵⁵ CHARGE Consortium meta-analysis
Lemaitre RN et al. Genetic loci associated with plasma phospholipid n-3 fatty acids: a meta-analysis of genome-wide association studies from the CHARGE Consortium. PLoS Genet, 2011, which examined 8,866 subjects of European ancestry across five cohorts. ELOVL2 minor alleles were robustly associated with higher plasma EPA (p=2×10⁻¹²), much higher DPA (p=1×10⁻⁴³), and significantly lower DHA (p=1×10⁻¹⁵) — a pattern that precisely matches a slowdown at the DPA→DHA elongation step: upstream metabolites accumulate while the downstream product (DHA) is reduced.

A direct supplementation study by Alsaleh and colleagues⁶⁶ Alsaleh and colleagues
Alsaleh A et al. ELOVL2 gene polymorphisms are associated with increases in plasma eicosapentaenoic and docosahexaenoic acid proportions after fish oil supplement. Genes Nutr, 2014 in 310 subjects found that ELOVL2 minor allele carriers had lower baseline plasma DHA but responded more strongly to fish oil supplementation: after 1.8 g/day EPA+DHA, minor allele carriers achieved approximately 30% higher EPA proportions and 9% higher DHA proportions than non-carriers. This paradox — lower baseline, larger response — is consistent with upregulation of an under-expressed enzyme when its substrate (EPA) is sharply increased.

The independent InCHIANTI/GOLDN genome-wide association study Tanaka et al.⁷⁷ Tanaka et al.
Tanaka T et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet, 2009 also identified the ELOVL2 region as a significant locus for plasma n-3 fatty acid levels in 1,075 elderly Italian subjects, replicated in 1,076 subjects from the GOLDN study.

For rs17606561 specifically, a 2015 birth cohort study Barman et al.⁸⁸ Barman et al.
Barman M et al. Single Nucleotide Polymorphisms in the FADS Gene Cluster but not the ELOVL2 Gene are Associated with Serum Polyunsaturated Fatty Acid Composition and Development of Allergy. Nutrients, 2015 found nominally lower 20:4n-6 in cord serum among rs17606561 carriers, though the association did not survive multiple-testing correction in this smaller cohort (n=211). A Chinese case-control study Sun et al.⁹⁹ Sun et al.
Sun C et al. FADS1-FADS2 and ELOVL2 gene polymorphisms in susceptibility to autism spectrum disorders in Chinese children. BMC Psychiatry, 2018 found nominal association between rs17606561 A allele and autism spectrum disorder risk (OR=1.63, pFDR=0.036), consistent with the known importance of DHA for neurodevelopment, though this requires replication in larger cohorts.

Practical Actions

The key implication is that A allele carriers rely more heavily on preformed DHA from the diet because their endogenous synthesis is less efficient. Plant-based omega-3 sources (flaxseed, chia, walnuts) provide ALA, but the conversion to DHA requires a functional ELOVL2 step that is partially impaired in A allele carriers. Marine-sourced EPA and DHA — from fatty fish or algae-based supplements — bypass this bottleneck entirely.

For heterozygous AG individuals, moderate supplementation with preformed EPA/DHA is advisable. For homozygous AA individuals, the endogenous synthesis impairment is more pronounced; higher intakes of preformed DHA are particularly important, especially for pregnant women (for fetal brain development) and older adults (for retinal and cognitive maintenance).

Interactions

ELOVL2 works in concert with FADS1 and FADS2, which handle the earlier desaturation steps (ALA→SDA→EPA). Variants in FADS1 (rs174547) and FADS2 (rs174537) that reduce desaturase activity compound with ELOVL2 impairment: reduced input to the elongase (less EPA) combined with reduced elongase efficiency creates a double bottleneck for DHA synthesis. Individuals carrying risk alleles in both FADS and ELOVL2 genes have the strongest case for relying on preformed marine DHA rather than plant-based ALA precursors.

TPMT (thiopurine S-methyltransferase) is the enzyme your body uses to inactivate thiopurine drugs¹¹ inactivate thiopurine drugs
Azathioprine, 6-mercaptopurine, and thioguanine — used for inflammatory bowel disease, autoimmune diseases, organ transplantation, and childhood leukemia by methylating them into harmless metabolites. When TPMT activity is reduced, these drugs shunt into an alternative pathway that generates toxic thioguanine nucleotides, which incorporate into DNA and can cause life-threatening bone marrow suppression at standard doses. The TPMT*3B variant (rs1800460) is the decreased-function star allele that, almost always, travels on the same chromosome as TPMT*3C (rs1142345) — and that pair-in-cis is what clinical labs call TPMT*3A, the most common TPMT deficiency haplotype in people of European ancestry.

The Mechanism

TPMT*3B is a single-nucleotide substitution in exon 7 (coding-strand c.460G>A, plus-strand C>T at chr6:18138997 because TPMT is on the minus strand) that changes alanine 154 to threonine (p.Ala154Thr), in a region critical for substrate binding and protein stability. On its own, the 3B substitution moderately reduces enzyme activity by destabilising the folded protein. What makes *3B clinically important is that it is almost always inherited together with *3C (p.Tyr240Cys) on the same chromosome — a configuration called **TPMT*3A*. The two amino acid changes together accelerate proteolysis of the enzyme²² accelerate proteolysis of the enzyme
Tai et al. PNAS 1997 showed TPMT*3A protein has a half-life roughly 15-fold shorter than wild-type, with near-complete degradation via the ubiquitin-proteasome pathway, leaving carriers with essentially no functional TPMT from the *3A allele. When TPMT cannot methylate thiopurine drugs, these medications are diverted almost entirely into pathways that generate toxic thioguanine nucleotides (TGNs), which incorporate into DNA and cause cytotoxicity — normally kept in check by TPMT methylation to the inactive 6-methylmercaptopurine metabolite — producing profound myelosuppression.

The Evidence

TPMT is one of the oldest and best-documented pharmacogenes. The CPIC guideline for thiopurine dosing³³ CPIC guideline for thiopurine dosing
Clinical Pharmacogenetics Implementation Consortium — Level A evidence, the highest tier for clinical implementation was first published in 2011 and has been updated multiple times since, recommending pre-treatment TPMT genotyping for all patients starting azathioprine, 6-mercaptopurine, or thioguanine. The original 2011 CPIC guideline⁴⁴ original 2011 CPIC guideline
Relling MV et al. Clin Pharmacol Ther 2011 named TPMT*2, *3A, *3B, and *3C as the four clinically relevant no-function alleles, and the 2018 update⁵⁵ 2018 update
Relling MV et al. Clin Pharmacol Ther 2019 extended the framework to NUDT15. The original molecular characterisation of TPMT*3A/*3B/*3C by Otterness et al.⁶⁶ Otterness et al.
Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997 found TPMT*3A (the *3B + *3C cis haplotype) in roughly 3.2-5.7% of Caucasian populations and in over 80% of Caucasian patients with deficient TPMT activity. A more recent genome-wide association study of TPMT enzyme activity⁷⁷ genome-wide association study of TPMT enzyme activity
Liu et al. Genomewide approach validates thiopurine methyltransferase activity as a monogenic pharmacogenomic trait. Clin Pharmacol Ther 2017 in 1,026 leukemia patients confirmed rs1800460 and rs1142345 as the two SNPs reaching genome-wide significance for TPMT activity, with TPMT being the only gene to reach that threshold. The FDA includes TPMT status in its pharmacogenomic biomarker table⁸⁸ pharmacogenomic biomarker table for azathioprine, mercaptopurine, and thioguanine, and the package inserts explicitly recommend genotyping or phenotyping before treatment.

Practical Implications

If you carry one or two copies of TPMT*3B, you are at risk for severe thiopurine-induced bone marrow suppression at standard doses. European populations carry the *3B variant at roughly 3.6% allele frequency, meaning about 7% of Europeans are heterozygotes (one functional TPMT allele) and roughly 1 in 800 are homozygous for *3B or compound heterozygous with another TPMT variant. The CPIC 2025 guideline recommends starting at 30-80% of the standard dose for intermediate metabolizers (one variant copy) and 10% of the standard dose or an alternative medication for poor metabolizers (two variant copies). Because TPMT deficiency classification depends on all variant alleles in combination, anyone with a *3B variant should also be checked for TPMT*3C, TPMT*2, and NUDT15 variants — especially if they have East Asian or admixed ancestry where NUDT15 is the dominant thiopurine safety gene.

Interactions

The dominant interaction for TPMT*3B is cis-haplotype configuration with TPMT*3C (rs1142345). In the overwhelming majority of Caucasian carriers, *3B and *3C are found on the same chromosome, forming the TPMT*3A haplotype⁹⁹ TPMT*3A haplotype
Otterness et al. found *3A accounted for ~84% of variant alleles in deficient Caucasians; *3B alone and *3C alone are each rare in isolation in this population. If your genome file shows you carry both rs1800460(T) and rs1142345(C), you most likely have TPMT*3A (both variants in cis on one chromosome) rather than two independent decreased-function alleles in trans. Clinical labs distinguish these configurations through phase determination, which requires long-read sequencing, family studies, or extended phenotyping — most SNP-array platforms cannot resolve cis vs trans without additional testing. This matters because *3A in cis behaves as a single deficient allele (heterozygote phenotype when one chromosome carries both variants), whereas *3B and *3C in trans (on separate chromosomes) would behave as compound heterozygous — two functional-null alleles — and produce the rare, severe poor-metabolizer phenotype.

A second critical interaction is with NUDT15 (rs116855232), the other thiopurine safety gene. NUDT15 loss-of-function variants are common in East Asian populations and act on a downstream step of thiopurine metabolism. Individuals carrying variants in both TPMT and NUDT15 require larger dose reductions than predicted by either gene alone, and both should be checked before thiopurine prescription. Finally, co-administration of allopurinol¹⁰¹⁰ allopurinol
Xanthine oxidase inhibitor used for gout; blocks an alternate thiopurine inactivation pathway or febuxostat with thiopurines creates a double-blockade that is particularly dangerous in TPMT variant carriers — the FDA label instructs reducing azathioprine to 25% of the standard dose when combined with allopurinol, and that reduction must be applied on top of any TPMT-based dose reduction.

The ADRB1 gene encodes the beta-1 adrenergic receptor¹¹ beta-1 adrenergic receptor
The primary receptor on cardiac muscle cells that binds adrenaline and noradrenaline, controlling heart rate, contractile force, and cardiac output in response to stress and exercise, the principal mediator of sympathetic nervous system control over the heart. When adrenaline and noradrenaline flood the bloodstream during exercise, stress, or danger, they bind this receptor and accelerate the heart. The Arg389Gly variant determines just how powerfully that signal is received.

At codon 389, most people carry the C allele (Arg389), which produces a receptor with higher basal coupling efficiency and stronger response to catecholamines. About 54% of Europeans are homozygous for this high-activity form; only 7% carry two copies of the reference G allele (Gly389). This makes Arg389 simultaneously the "variant" allele in name and the dominant allele in practice. The variant's importance lies not in rarity but in its influence on exercise heart rate response, beta-blocker pharmacogenomics, and myocardial infarction risk.

The Mechanism

At position 389 in the intracellular C-terminal tail of the receptor, the amino acid change from glycine (G allele) to arginine (C allele) alters the geometry of the region that couples to Gs protein²² Gs protein
The stimulatory G-protein that activates adenylyl cyclase when bound by a ligand-occupied receptor, generating cAMP as the intracellular second messenger. The Arg389 form has enhanced basal cAMP³³ cAMP
Cyclic adenosine monophosphate — the intracellular messenger that triggers protein kinase A activity, ultimately increasing heart rate and contractile force production even without catecholamine stimulation, and generates a larger cAMP surge when adrenaline binds compared to the Gly389 form.

This is not merely a quantitative difference. A 2008 cardiac gene expression study⁴⁴ 2008 cardiac gene expression study
Swift SM et al. Differential coupling of Arg- and Gly389 polymorphic forms of the beta1-adrenergic receptor leads to pathogenic cardiac gene regulatory programs. Physiol Genomics, 2008 using human heart tissue found that Arg389 receptor activation uniquely upregulates genes involved in inflammation, programmed cell death, and extracellular matrix remodeling — signaling programs not activated by the Gly389 form. This divergence in downstream gene regulation may explain why the genotype predicts differential cardiovascular outcomes and drug responses.

The Evidence

Exercise Heart Rate Response: The pharmacogenomic signature of this variant is most directly demonstrated in exercise contexts. A controlled study of 27 healthy adults⁵⁵ controlled study of 27 healthy adults
Muszkat M et al. The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β(1) adrenergic receptor antagonist esmolol in healthy individuals. Pharmacogenet Genomics, 2013 administered intravenous esmolol (an ultra-short-acting beta-1 blocker) during exercise. The inhibition of exercise-induced heart rate increase was 0.78 bpm in Gly389 homozygotes, 5.11 bpm in heterozygotes, and 10.22 bpm in Arg389 homozygotes — a 13-fold difference (p = 0.014). This dose-dependent genotype effect confirms that Arg389 carriers have a stronger adrenergic drive on exercise heart rate, and a correspondingly stronger response to blockade.

A study of 35 healthy subjects⁶⁶ study of 35 healthy subjects
Yogev D et al. Effects of sex and the common ADRB1 389 genetic polymorphism on the hemodynamic response to dobutamine. Pharmacogenet Genomics, 2015 using dobutamine infusion (a synthetic catecholamine) found that Arg389Arg homozygotes showed a 4.7-fold greater resting heart rate increase (12.95 vs 2.75 bpm) and a 3.9-fold greater renin response than Gly389Gly individuals. Heterozygotes showed intermediate responses. Genotype was the primary determinant in multivariate analysis (p = 0.011).

Beta-Blocker Response in Heart Failure: The most clinically impactful finding concerns beta-blocker dose optimization in heart failure. A pooled analysis of the BEST and HF-ACTION trials⁷⁷ pooled analysis of the BEST and HF-ACTION trials
Parikh KS et al. Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med, 2018 (combined N = 1,997 patients) found that Arg389Arg homozygotes on high-dose beta-blocker therapy had a 60% reduction in all-cause mortality (HR 0.40, p = 0.002), compared to no significant benefit in Gly allele carriers (p > 0.2). Critically, at low doses, Arg389Arg individuals actually showed increased mortality (HR 1.83, p = 0.015) — suggesting that underdosing may be harmful in this genotype. A 2022 pharmacogenomics study⁸⁸ 2022 pharmacogenomics study
Guerra LA et al. Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers. Pharmacogenomics J, 2022 confirmed this interaction: Arg389 carriers derived greater survival benefit at higher beta-blocker doses (p_interaction = 0.043).

Acute MI and Cardioprotection: In a Japanese case-control study⁹⁹ Japanese case-control study
Iwai C et al. Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J, 2003 of 354 AMI patients versus 354 matched controls, Arg389 homozygotes had an odds ratio of 2.86 (95% CI 1.92–4.26, p = 0.0001) for nonfatal MI, independent of classical risk factors. This risk likely reflects the enhanced sympathetic activation of the Arg389 receptor, which can drive adverse myocardial remodeling. Consistent with this, a 2025 clinical trial analysis¹⁰¹⁰ 2025 clinical trial analysis
Clemente-Moragón A et al. Pharmacogenomics and chronotherapy of drug-induced cardioprotection in acute myocardial infarction. Nat Commun, 2025 found that metoprolol reduced infarct size exclusively in Arg389 homozygotes; Gly389 carriers received no cardioprotective benefit, with in-silico modeling showing unstable metoprolol binding to the Gly389 variant.

Blood Pressure Response: A Chinese study of 87 hypertensives¹¹¹¹ Chinese study of 87 hypertensives
Si D et al. Association of common polymorphisms in β1-adrenergic receptor with antihypertensive response to carvedilol. J Cardiovasc Pharmacol, 2014 found that Arg389 homozygotes had a 4-fold greater diastolic blood pressure reduction on carvedilol (10.61 vs 2.62 mmHg, p = 0.013), suggesting that genotype-guided prescribing could optimize antihypertensive therapy.

Practical Implications

For Arg389Arg (CC) individuals: your beta-1 receptors have higher basal activity and generate a stronger heart rate and blood pressure response to sympathetic stimulation. In heart failure or post-MI contexts, high-dose beta-blocker therapy is particularly important and effective for you. Inform your cardiologist of this genotype if you have cardiovascular disease.

For Gly389Gly (GG) individuals: your receptors have lower basal coupling efficiency, resulting in blunted catecholamine response. Beta-blocker response is weaker and may not confer the same survival benefits in heart failure. In acute MI, metoprolol-based cardioprotection may not apply to your genotype.

For heterozygotes (CG): your response profile is intermediate, tracking dose-dependently with the number of Arg389 alleles.

Interactions

ADRB1 Arg389Gly interacts with the ADRB1 Ser49Gly variant (rs1801252) to form functionally distinct haplotypes. The Ser49/Arg389 haplotype (the more active combination) has been associated with greater beta-blocker benefit in several studies. Petersen et al. (2011) found that Arg389 homozygotes combined with the ADRB2 Gln27 (rs1042714) variant had doubled mortality on carvedilol but not on metoprolol, suggesting that beta-blocker choice may matter when multiple adrenergic receptor variants are present.

The CLOCK gene (Circadian Locomotor Output Cycles Kaput) encodes the master transcription factor¹¹ transcription factor
A protein that binds to DNA and activates the expression of other genes, in this case driving the ~24-hour circadian rhythm at the heart of the mammalian circadian clock. Working with its partner BMAL1, the CLOCK protein drives rhythmic expression of thousands of genes that govern sleep-wake cycles, hormone secretion, metabolism, and body temperature. The rs1801260 variant — commonly called 3111T>C using the coding strand notation — sits in the 3' untranslated region (3'UTR)²² 3' untranslated region (3'UTR)
The section of mRNA after the stop codon that doesn't code for protein but regulates mRNA stability, localization, and translation efficiency of CLOCK mRNA, where it affects how long the messenger RNA persists in the cell before being degraded.

This was the first human clock gene polymorphism linked to chronotype, identified in a landmark 1998 study³³ landmark 1998 study
Katzenberg D et al. A CLOCK polymorphism associated with human diurnal preference. Sleep, 1998 at Stanford. Carriers of the minor allele scored significantly lower on the Horne-Ostberg morningness-eveningness questionnaire, indicating a shift toward evening preference that was independent of age, sex, and ethnicity.

The Mechanism

The rs1801260 variant falls within a miR-182 binding site⁴⁴ miR-182 binding site
MicroRNA-182 binds to the 3'UTR of CLOCK mRNA and promotes its degradation; the variant allele disrupts this binding in the CLOCK 3'UTR. The minor allele (G on plus strand, C in coding strand notation) disrupts this microRNA interaction site, resulting in increased CLOCK mRNA stability. Cell-based studies using mouse embryonic fibroblasts transfected with the rs1801260 construct showed that the variant allele produces significantly higher levels of CLOCK and downstream Per2 mRNA.

Higher CLOCK protein levels extend the active phase of the transcription-translation feedback loop⁵⁵ transcription-translation feedback loop
The core circadian mechanism: CLOCK/BMAL1 activate PER and CRY genes, whose proteins then inhibit CLOCK/BMAL1, creating a ~24-hour oscillation that defines circadian period length. This molecular shift manifests behaviorally as delayed sleep onset, higher evening activity, and a preference for later bed and wake times.

The Evidence

The original Katzenberg study⁶⁶ original Katzenberg study
Katzenberg D et al. A CLOCK polymorphism associated with human diurnal preference. Sleep, 1998 genotyped 410 adults from a population-based sample and found that C allele carriers had significantly lower Horne-Ostberg scores (shifted toward eveningness), independent of age, sex, and ethnic background.

Benedetti et al. (2007)⁷⁷ Benedetti et al. (2007)
Benedetti F et al. Actimetric evidence that CLOCK 3111 T/C SNP influences sleep and activity patterns in patients affected by bipolar depression. Am J Med Genet B Neuropsychiatr Genet, 2007 provided objective actimetric data in 39 bipolar depressed inpatients, showing that C allele carriers had 79 minutes later sleep onset and 75 fewer minutes of total sleep compared to T/T homozygotes, with higher evening activity levels — all despite similar depression severity.

The metabolic consequences of this chronotype shift have been well documented. Garaulet et al. (2010)⁸⁸ Garaulet et al. (2010)
Garaulet M et al. CLOCK gene is implicated in weight reduction in obese patients participating in a dietary programme based on the Mediterranean diet. Int J Obes, 2010 studied 1,100 overweight and obese subjects and found that minor allele carriers lost significantly less weight during a Mediterranean diet intervention (P = 0.008), with more carriers being short sleepers (59% vs 41%, P < 0.05).

Garcia-Rios et al. (2014)⁹⁹ Garcia-Rios et al. (2014)
Garcia-Rios A et al. Beneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in metabolic syndrome. Chronobiol Int, 2014 found significant gene-diet interactions in 475 metabolic syndrome patients: after 12 months on a low-fat diet, major allele homozygotes (AA) showed lower insulin and HOMA-IR, while minor allele carriers did not improve as much (interaction P = 0.009 for insulin, P = 0.014 for HOMA-IR).

An association with adult ADHD¹⁰¹⁰ association with adult ADHD
Kissling C et al. A polymorphism at the 3'-untranslated region of the CLOCK gene is associated with adult attention-deficit hyperactivity disorder. Am J Med Genet B, 2008 was found in 143 subjects (P < 0.001), consistent with the known circadian rhythm disruption in ADHD.

It is important to note that large genome-wide association studies of chronotype have not consistently replicated the rs1801260 signal. This may reflect the modest effect size of any single variant and the polygenic nature of chronotype, where hundreds of variants each contribute small effects.

Practical Implications

The CLOCK 3111C allele is not a sleep disorder — it is a common variant that tilts circadian preference toward eveningness. The practical relevance is in recognizing this tendency and structuring daily routines to work with it rather than against it.

For weight management, the evidence suggests that minor allele carriers may benefit from paying particular attention to meal timing, eating the main meal earlier in the day, and avoiding late-night eating. The combination of evening preference and shorter sleep creates a metabolic environment that favors weight gain through altered ghrelin, GLP-1, and insulin dynamics.

Light exposure is the strongest environmental cue for circadian entrainment. Morning bright light exposure (10,000 lux for 20-30 minutes upon waking) can help shift the circadian phase earlier, partially counteracting the genetic evening tendency. Conversely, evening blue light from screens further delays sleep onset in already evening-shifted individuals.

Interactions

The CLOCK 3111C allele interacts with SIRT1 variants to produce additive effects on evening preference and weight loss resistance. Garaulet et al. (2012) showed that carriers of minor alleles at both SIRT1 (rs1467568) and CLOCK (rs1801260) had the strongest evening preference and greatest resistance to weight loss in a behavioral obesity treatment.

CLOCK also interacts functionally with PER2 and PER3 — the period genes that form the negative limb of the circadian feedback loop. While specific gene-gene interaction studies for rs1801260 with PER variants are limited, the biological pathway logic is strong: increased CLOCK expression drives higher PER/CRY production, and variants in PER genes that alter this response could compound the circadian shift.